A marketing authorization application was filed by Janssen-Cilag, a Johnson & Johnson unit, with the European Medicines Agency for ibrutinib, a once-daily drug to treat two kinds of blood cancer. The drug is intended for adults with relapsed or refractory mantle cell lymphoma and for those with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia.

Related Summaries